Known allergy or hypersensitivity to aspirin, iodides, or any NSAID, including piroxicam.
CV: Edema; weight gain; CHF; alterations in BP; vasodilation; palpitations; tachycardia.
CNS: Headache; malaise; dizziness; somnolence; vertigo; depression; insomnia; nervousness.
DERM: Pruritus; rash; sweating; erythema; bruising; desquamation; erythema multiforme; toxic epidermal necrolysis.
EENT: Tinnitus; swollen eyes; blurred vision; eye irritation; rhinitis; pharyngitis.
GI: Epigastric distress; nausea; vomiting; anorexia; constipation; stomatitis; abdominal discomfort; diarrhea; flatulence; abdominal pain; indigestion; toxicity (bleeding, ulceration, perforation); heartburn; dyspepsia; anorexia.
GU: Hematuria; proteinuria; increased BUN and serum creatinine; acute renal insufficiency and failure; papillary necrosis; interstitial nephritis; nephrotic syndrome; hyperkalemia; hyponatremia.
HEMA: Increased bleeding time; decreased Hgb and Hct; anemia; leukopenia; eosinophilia, thrombocytopenia.
HEPA: Increased LFTs; elevated liver enzymes.
RESP: Bronchospasm; laryngeal edema; dyspnea; hemoptysis; shortness of breath.
May augment risk of GI bleeding.
May increase effect of anticoagulants because of decreased plasma protein binding and inhibition of platelet aggregation. May increase risk of gastric erosion and bleeding.
Antihypertensive effect may be decreased.
Effects of piroxicam may be decreased.
May decrease lithium Cl.
May increase methotrexate levels and toxicity.
May increase concentrations and possibly the toxicity of piroxicam by inhibiting its metabolism.
Therapeutic Classification: antirheumatics, nonsteroidal anti-inflammatory agents
Absorption: Well absorbed from the GI tract.
Distribution: Unknown. Enters breast milk in small amounts.
Metabolism/Excretion: Mostly metabolized by the liver. Minimal amounts excreted unchanged by the kidneys.
Half-life: 50 hr.
Copyright ©Nims Drugs2015. All rights reserved.
Powered by : web creation Nepal